Introduction
Metabolic syndrome (MetS) is a growing concern among patients with schizophrenia 1 because metabolic adverse events are widely regarded as a major risk factor for cardiovascular diseases 2,3 and mortality. 4, 5 Although the causes of metabolic adverse events are complicated, the risk factors among patients with schizophrenia are attributed to dietary habits, 6 physical activity, 7 antipsychotic medications, 8, 9 and negative symptoms of schizophrenia. 10 Although the opinion of psychiatrists is well known concerning this issue, [11] [12] [13] [14] those of the patients most affected by metabolic adverse events are relatively unexplored; nevertheless, they are important factors. Educational programs for these patients might effectively improve their clinical outcomes. 15 To date, some studies have assessed patient attitudes toward antipsychotic medications. [16] [17] [18] [19] [20] However, these studies have not primarily focused on metabolic adverse events. Thus, it is necessary to accurately assess patient attitudes toward metabolic issues in a representative sample of patients. Currently, Japan has 28.4 psychiatric beds per 10,000 people, which is the highest ratio in the world. Furthermore, the mean length of hospital stay in Japan is ~1.5 years, which represents the longest stay among developed nations. 21 Because inpatients with schizophrenia receive controlled meals and occupational therapy, their lifestyles might differ from those of outpatients. A previous study conducted in Japan showed that the rates of MetS in outpatients and inpatients with schizophrenia were 48.1% and 15.8%, respectively. 22 Although the shift from inpatient care to community-based care is an ongoing challenge, the discharge of long-term psychiatric patients might elevate their risk of MetS. We previously reported the psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia. 14 However, attitudes of schizophrenic patients themselves had not been assessed in Japan.
The current study investigated attitudes toward metabolic adverse events in a nationwide survey of Japanese patients with schizophrenia. To our knowledge, this study uses the largest sample of these patients, and it is the first to investigate attitudes toward metabolic issues among Asian patients.
Methods

Procedure
The joint committee of the Japanese Society of Clinical Neuropsychopharmacology and the Japan Psychiatric Hospital Association for antipsychotic treatment and physical risk prepared this survey. After reviewing the relevant literature and extant guidelines, a brief questionnaire was constructed to cover patient recognition of the following broad areas: dietary habits, lifestyle, self-monitoring, knowledge, and medical practice ( Figure S1 ). Between January 2012 and June 2013, the questionnaire was mailed to patients associated with 520 outpatient facilities and 247 inpatient facilities belonging to the Japan Psychiatric Hospital Association. Participants have been selected based on the available sampling method and diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, or International Classification of Diseases, tenth revision.
All respondents provided written informed consent to participate in this study without any incentive. The anonymous questionnaire was the only research instrument, and a statement was included that states, "The completion of the attached questionnaire will be taken as indicating your consent to participate". The Ethics Committee at the Japan Psychiatric Hospital Association and the Hirosaki University School of Medicine approved the study procedure.
statistical analysis
Descriptive statistics were computed to describe the demographic and clinical variables. In order to compare the main demographic and clinical characteristics between inpatients and outpatients, the Mann-Whitney U-test was performed to analyze continuous variables, and a chi-square test was performed to analyze categorical variables. A value of P,0.05 was considered significant. Parameter r was used to measure the effect size of Mann-Whitney U-test, and r values of 0.3 represent medium effect sizes. Strength of association on a chi-square analysis was confirmed with a medium phi and Cramer's V score of 0.30. The data were analyzed using the SPSS software for Windows (Version 23.0).
Results
The demographic characteristics of the study participants are listed in Table 1 .
Patient recognition of dietary habits
Approximately 27.9% (4,136/14,840) of inpatients stated that they drank soft drinks (eg, cola; Q1) every day, 34.6% (5,142/14,840) did so more than once a week, 18.3% (2,718/14,840) did so more than once a month, and 19.2% (2,844/14,840) did not drink any, whereas 27.8% (1,841/6,616) of outpatients stated that they drank soft drinks every day, 28.5% (1,884/6,616) did so more than once a week, 25.8% (1,706/6,616) did so more than once a month, and 17.9% (1,185/6,616) did not drink any (Q1; Cramer's V=0.092, P,0.001). Approximately 62.8% (9,324/14,841) of inpatients consumed 100% of three meals a day (Q2), Notes: Phi represents the effect size for chi-square test; "Other" participants answered that they are mindful of other healthy habits; "None" participants answered that they are not mindful of any healthy habits. 
Discussion
The present study employed a national survey in Japan that evaluated attitudes toward metabolic adverse events among patients with schizophrenia. More than half of outpatients felt obese, and more than half of all respondents hoped to receive regular blood tests to prevent metabolic adverse events. However, a minority of patients were mindful of eating balanced meals and having physical exercise and stated that their doctors encouraged them to have such habits. Our results confirm that patients with schizophrenia are concerned about metabolic adverse events but do not have healthy lifestyle habits. The differences in dietary patterns between patients with schizophrenia and healthy controls have been reported previously. 23, 24 Inadequate dietary patterns can cause obesity, 25 MetS, 26 and cardiovascular events. 27 In our survey, most outpatients stated that they ate breakfast, lunch, and dinner regularly. However, more than one-third of our respondents ate cake and other sweets at least once a day, and most participants stated that they were not mindful of having a healthy diet. Dietary improvements in patients with schizophrenia might help prevent metabolic adverse events. 28 Reduced physical activity might play a role in the development of MetS, 29 and a previous study reported that patients with schizophrenia engaged in physical activity less frequently than healthy controls. 30 In this survey, approximately half of our respondents (55% of inpatients and 45% of outpatients) answered that they did not exercise at all. Our results are in accordance with previous research, 31 which found that 40% of individuals with schizophrenia report a lack of moderate physical activity, and 75% report a lack of vigorous physical activity. Although a minority of respondents (inpatients 29.4%, outpatients 39.5%) were mindful of having physical exercise, several studies have indicated that regular exercise programs are possible among individuals with schizophrenia and that they can have beneficial effects on their well-being as well as their physical and mental health. 32 According to our survey, more than half of outpatients reported that they felt obese. Obesity is a growing public health concern, and it is becoming more prevalent among patients with schizophrenia compared with the general population. [33] [34] [35] Previous studies have shown that being overweight is a major risk factor for MetS, cardiovascular diseases, and premature death. [36] [37] [38] Additionally, obesity among patients with schizophrenia is associated with high medication costs, 39 low self-esteem, poor psychosocial adaptation, 40 reduced quality of life, 41, 42 negative attitudes toward medication, 19 and noncompliance with antipsychotic medication regimes. 43 Although behavioral interventions can effectively prevent and reduce antipsychotic-associated weight gain and cardiometabolic perturbations, 15 most respondents in this study reported that they were not encouraged by their doctors to perform moderate physical exercise.
More than half of our respondents hoped to receive blood tests regularly to prevent weight gain and diseases such as diabetes. Although patients with severe mental illnesses are less aware of comorbid medical conditions such as heart disease, diabetes, and hypertension, 17 patients judged disorders such as epilepsy and diabetes as worse than schizophrenia 16 and described dissatisfaction or deficiency with regard to the care that they received from their health care providers. 18 Buckley et al showed that most psychiatrists did not routinely monitor their patients' lipid profiles, blood glucose levels, or blood pressure. 12 We previously reported that most psychiatrists in Japan monitor the lipid profiles and blood glucose levels of their inpatients and outpatients more than twice a year. 14 Most psychiatrists stated that the frequency at which they monitored patients under antipsychotic treatment was based on their own clinical experience. However, only 20.6% of respondents stated that this monitoring frequency was sufficient to reduce metabolic risk. It is necessary to disseminate monitoring guidelines with regard to metabolic adverse events because they might make psychiatrists more aware of an integral approach to patients with schizophrenia, thereby increasing the physical health monitoring of these patients. 44 In Japan, the Mental Health Act seeks to promote the concept of "normalization", establishing mental illness as a disability and encouraging the re-assimilation of psychiatric inpatients back into the community. Although inpatients were encouraged to shift to community-based care, most inpatients did not have enough knowledge of metabolic adverse events. Educational programs seeking to prepare long-term hospitalized patients with schizophrenia for discharge from hospitals are warranted.
The current study also has some limitations. Firstly, our study is limited by the fact that it is cross-sectional rather than prospective in design and lacks data on the actual practices of psychiatrists. This study could not clarify a causal relationship between the psychiatrists' practice and attitudes among patients with schizophrenia. Secondly, several potential confounding factors, such as antipsychotic medications, duration of illness, and treatment, were not assessed by our study. Thirdly, mean age of inpatients was older than that of outpatients. Age could affect the results of dietary habits, lifestyle, self-monitoring, knowledge, and medical practices.
Conclusion
This study showed that only a minority of patients were mindful of eating balanced meals and having physical exercise; however, more than half of patients hoped to prevent weight gain and diabetes. These findings imply that educational efforts 45 and the promotion of the best pharmacotherapy and monitoring practices 46 are needed for patients with schizophrenia. Improving attitudes toward metabolic adverse events among these patients might contribute to physical health improvements. 
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